Tuberculosis into the next century

Journal of Medical Microbiology

Volumn 44, Issue 1, 1996, Pages 1-34

  Hart, C A ^b   Beeching, N J ^b   Duerden, B I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AZITHROMYCIN; BCG VACCINE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OXAZOLIDINONE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; BACTERIAL VIRULENCE; CHILD; FUTUROLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MOLECULAR BIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINATION; AIDS RELATED COMPLEX; CONFERENCE PAPER; DRUG EFFECT; DRUG RESISTANCE; GENETICS; PATHOGENICITY; STANDARD; VIRULENCE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; BCG VACCINE; DRUG RESISTANCE; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VIRULENCE;

EID: 0030048607     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-44-1-1     Document Type: Review

References (286)

1. Cave AJE. The evidence for the incidence of tuberculosis in ancient Egypt, Br J Tuberc 1939; 33: 142-152.
2. Manchester K. Tuberculosis and leprosy in antiquity: an interpretation. Med Hist 1984; 28: 162-173.
3. Formicola V, Milanesi Q, Scarsini C. Evidence of spinal tuberculosis at the beginning of the fourth millennium BC from Arene Candide Cave (Liguria, Italy). Am J Phys Anthropol 1987; 72: 1-6.
4. Ritchie WA. Paleopathological evidence suggesting pre-Columbian tuberculosis in New York State. Am J Phys Anthropol 1952; 10: 305-317.
5. Pfeiffer S. Paleopathology in an Iroquoian ossuary with special reference to tuberculosis. Am J Phys Anthropol 1984; 65: 181-189.
6. Stirland A, Waldron T. The earliest cases of tuberculosis in Britain. J Arch Sci 1990; 17: 221-230.
7. Buchan W. Domestic Medicine or a treatise on the cure and prevention of diseases. Newcastle, UK, Mackenzie and Dent, 1813: 180-192.
8. Lowell AM, Edwards LB, Palmer CE. Tuberculosis, vital and health statistics monographs, Cambridge, MA, American Harvard University Press, 1969.
9. Villernin JA, Études sur la tuberculose. Paris, Ballière, 1868.
10. Koch R. Die aetiologie der tuberculose. Berliner Klinische Wochenschrift 1882; 19: 221-230.
11. Koch R. The aetiology of tuberculosis (English translation). Rev Infect Dis 1982; 4: 1270-1274.
12. Dubos R, Dubos J. The white plague: tuberculosis, man and society. Boston USA, Little Brown, 1952.
13. Paul H. Tuberculosis. The control of diseases. Edinburgh, E and J Livingstone, 1964: 222-254.
14. Iseman MD, Madsen LA. Drug resistant tuberculosis. Clin Chest Med 1989; 10: 341-353.
15. Nisar M, Narula M, Beeching N, Davies PDO. HIV related tuberculosis in England and Wales. Tubercle Lung Dis 1992; 73: 200-202.
16. Hayward AC, Watson JM. Tuberculosis in England and Wales 1982-1993: notifications exceeded predictions: CDR Rev 1995; 3: R29-R33.
17. Spence DPS, Hotchkiss J, Williams CSD, Davies PDO. Tuberculosis and poverty. BMJ 1993; 307: 759-761.
18. Davies PDO. Tuberculosis and migration. J R Coll Phys Lond 1995; 29: 113-118.
19. Mangtani P, Jolley DJ, Watson JM, Rodrigues LC. Socioeconomic deprivation and notification rates for tuberculosis in London during 1982 91. BMJ 1995; 310: 963-966.
20. Bhatti N, Law MR, Morris JK, Halliday R, Moore-Gillon J. Increasing incidence of tuberculosis in England and Wales: a study of likely causes. BMJ 1995; 310: 967-969.
21. Watt B, Rayner A, Harris G. Modern methods in mycobacteriology. Rev Med Microbiol 1993; 4: 97-105.
22. Mabilat C, Desvarenne S, Panteix G et al. Routine identification of Mycobacterium tuberculosis complex isolates by automated hybridization. J Clin Microbiol 1194; 32: 2702-2705.
23. Hawkey PM. The role of polymerase chain reaction in the diagnosis of mycobacterial infections. Rev Med Microbiol 1994; 5: 21-32.
24. van Embden JDA, Cave MD, Crawford JT et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-409.
25. Rogall T, Flohr T, Bottger EC. Differentiation of Mycobacterium species by direct sequencing of amplified DNA. J Gen Microbiol 1990; 136: 1915-1920.
26. Ross BC, Dwyer B. Rapid, simple method for typing isolates of Mycobacterium tuberculosis by using the polymerase chain reaction. J Clin Microbiol 1993; 31: 329-334.
27. Brisson-Noel A, Gicquel B, Lecossier D et al. Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Lancet 1989; 4: 1069-1071.
28. Pierre C, Lecossier D, Boussougant Y et al. Use of a reamplification protocol improves sensitivity of detection of Mycobacterium tuberculosis in clinical samples by amplification of DNA. J Clin Microbiol 1991; 29: 712-717.
29. Thierry D, Cave MD, Eisenach KD et al. IS6110, an IS-like element of M. tuberculosis complex. Nucleic Acids Res 1990; 18; 188.
30. Kok AHJ, Schuitema ARJ, Kuijper S et al. Detection of Mycobacterium tuberculosis is clinical samples by using polymerase chain reaction and a nonradioactive detection system. J Clin Microbiol 1992; 30: 2567-2575.
31. Shankar P, Manjunath N, Lakshmi R, Aditi B, Seth P, Shriniwas. Identification of Mycobacterium tuberculosis by polymerase chain reaction. Lancet 1990; 335: 423.
32. Drobniewski FA, Kent RJ, Stoker NG, Uttley AHC. Molecular biology in the diagnosis and epidemiology of tuberculosis. J Hosp Infect 1994; 28: 249-263.
33. Walker DA, Taylor IK, Mitchell DM, Shaw RJ. Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65 kDa antigen gene, in the diagnosis of tuberculosis. Thorax 1992; 47: 690-694.
34. de Lassence A, Lecossier D, Pierre C et al. Detection of mycobacterial DNA in pleural fluid from patients with tuberculous pleurisy by means of the polymerase chain reaction: comparison of two protocols. Thorax 1992; 47: 265-269.
35. Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650.
36. Buck GE, O'Hara LC, Summersgill JT. Rapid, simple method for treating clinical specimens containing Mycobacterium tuberculosis to remove DNA for polymerase chain reaction. J Clin Microbiol 1992; 30: 1331-1334.
37. Zwadyk P, Down JA, Myers N, Dey MS. Rendering of mycobacteria safe for molecular diagnostic studies and development of a lysis method for strand displacement amplification and PCR. J Clin Microbiol 1994; 32: 2140-2146.
38. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. A one-step microbial DNA extraction method using "Chelex 199" suitable for gene amplification. Res Microbiol 1992; 143: 785-790.
39. Kolk AHJ, Noordhoek GT, de Leeuw O, Kuijper S, van Embden JDA. Mycobacterium smegmatis strain for detection of Mycobacterium tuberculosis by PCR used as internal control for inhibition of amplification and for quantification of bacteria. J Clin Microbiol 1994; 32: 1354-1356.
40. Brisson-Noel A, Aznar C, Chureau C et al. Diagnosis of tuberculosis by DNA amplification in clinical practice evaluation. Lancet 1991; 338: 364.
41. Eisenach KD, Sifford MD, Cave MD et al. Detection of Mycobacterium tuberculosis in sputum samples using a polymerase chain reaction. Am Rev Respir Dis 1991; 144: 1160-1163.
42. Kox LFF, Rhienthong D, Miranda AM et al. A more reliable PCR for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 1994; 32: 672-678.
43. Noordhoek GT, Kolk AHJ, Bjune G et al. Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol 1994; 32: 277-284.
44. Shinnick TM, Jones V. Molecular approaches to the diagnosis of tuberculosis. In: Bloom, BR (ed) Tuberculosis: pathogenesis, protection and control. Washington, DC, American Society for Microbiology. 1994; 32: 517-530.
45. Jones V, Alden MJ, Curry JI et al. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by amplification of rRNA. J Clin Microbiol 1993; 31: 2410-2416.
46. Miller N, Hernandez SG, Cleary TJ. Evaluation of Gen-Probe amplified Mycobacterium tuberculosis direct test and PCR for direct detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 1994; 32: 393-397.
47. Pfyffer GE, Kissling P, Wirth R, Weber R. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system. J Clin Microbiol 1994; 32: 918-923.
48. Small PM, van Embden JDA. Molecular epidemiology of tuberculosis. In: Bloom BR (ed) Tuberculosis: pathogenesis, protection and control. Washington, DC, American Society for Microbiology. 1994; 32: 1542-1546.
49. McAdam RA, Hermans PWM, van Soolingen D et al. Characterization of a Mycobacterium tuberculosis insertion sequence belonging to the IS3 family. Mol Microbiol 1990; 4: 1607-1613.
50. Hermans PWM, van Soolingen D, Bik EM, de Haas PEW, Dale JW, van Embden JDA. The insertion element IS987 from Mycobacterium bovis BCG is located in a hot spot integration region for insertion elements in M. tuberculosis complex strains. Infect Immun 1991; 59: 2695-2705.
51. Collins DM, Stephens DM. Identification of insertion sequence, IS1081, in Mycobacterium bovis. FEMS Microbiol Lett 1991; 83: 11-16.
52. van Soolingen D, Hermans PWM, de Haas PEW, van Embden JDA. Insertion element IS1081-associated restriction fragment length polymorphism in Mycobacterium tuberculosis complex species: a reliable tool for recognizing Mycobacterium bovis BCG. J Clin Microbiol 1992; 30: 1772-1777.
53. Groenen PMA, Bunschoten AE, van Soolingen D, van Embden JDA. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differ-entiation by a novel typing method. Mol Microbiol 1993; 10: 1057-1065.
54. Hermans PWM, van Soolingen D, van Embden JDA. Characterization of a major polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae. J Bacteriol 1992; 174: 4157-4165.
55. 5 as a marker for Mycobacterium tuberculosis strain identification. J Clin Microbiol 1994; 32: 1318-1321.
56. van Soolingen D, de Haas PEW, Hermans PWM, Groenen PMA, van Embden JDA. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol 1993; 31: 1987-1995.
57. van Soolingen D, de Haas PEW, Hermans PWM, van Embden JDA. DNA fingerprinting of Mycobacterium tuberculosis. In: Clark VL, Bavoil D (eds) Methods in enzymology. London, Academic Press. 1994; 235: 196-205.
58. Das S, Chan SL, Allen BW, Mitchison DA, Lowrie DB. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tubercle Lung Dis 1993; 74: 47-51.
59. van Soolingen D, Hermans PWM, de Haas PEW, Soll DR, van Embden JDA. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991; 29: 2578-2586.
60. Cave MD, Eisenach KD, Templeton G et al. Stability of DNA fingerprint pattern produced with IS6110 in strains of Mycobacterium tuberculosis. J Clin Microbiol 1994; 32: 262-266.
61. Daley CL, Small PM, Schecter GF et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-235.
62. Coronado VG, Beck-Sague CM, Hutton MD et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993; 168: 1052-1055.
63. Jereb JA, Burwin KR, Dooley SW et al. Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates. J Infect Dis 1993; 168: 1219-1224.
64. Yuen LKW, Ross BC, Jackson KM, Dwyer B. Characterization of Mycobacterium tuberculosis strains from Vietnamese patients by Southern blot hybridization. J Clin Microbiol 1993; 31: 1615-1618.
65. Yang ZH, de Haaz PEW, van Soolingen D, van Embden JDA, Andersen AB. Restriction fragment length polymorphism of Mycobacterium tuberculosis strains isolated from Greenland during 1992; evidence of tuberculosis transmission between Greenland and Denmark. J Clin Microbiol 1994; 32: 3018-3025.
66. Genewein A, Telenti A, Bernasconi C et al. Molecular approaches to identifying route of transmission of tuberculosis in the community. Lancet 1993; 342: 841-844.
67. Godfrey-Faussett P, Stoker NG. Aspects of tuberculosis in Africa. 3. Genetic 'fingerprinting' for clues to the pathogenesis of tuberculosis. Trans R Soc Trop Med Hyg 1992; 86: 471-475.
68. Chevrel-Dellagi D, Abderrahman A, Haltiti R, Koubaji H, Gicquel B, Dellagi K. Large-scale DNA fingerprinting of Mycobacterium tuberculosis strains as a tool for epidemiological studies of tuberculosis. J Clin Microbiol 1993; 31; 2446-2450.
69. Small PM, McClenny NB, Singh SP, Schoolnik GK, Tompkins LS, Michelsen PA. Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol 1993; 31: 1677-1682.
70. Collins DM, Erasmuson SK., Stephens DM, Yates GF, de Lisle GW. DNA fingerprinting of Mycobacterium bovis strains by restriction fragment analysis and hybridization with insertion elements IS1081 and IS6110. J Clin Microbiol 1993; 31: 1143-1147.
71. Skuce RA, Brittain D, Hughes MS, Beck L-A, Neill SD. Genomic fingerprinting of Mycobacterium bovis from cattle by restriction fragment length polymorphism analysis. J Clin Microbiol 1994; 32: 2387-2392.
72. Palittapongarnpim P, Chomyc S, Fanning A, Kunimoto D. DNA fragment length polymorphism analysis of Mycobacterium tuberculosis isolates by arbitrarily primed polymerase chain reaction. J Infect Dis 1993; 167: 975-978.
73. Linton CJ, Jalal H, Leeming JP, Millar MR. Rapid discrimination of Mycobacterium tuberculosis strains by random amplified polymorphic DNA analysis. J Clin Microbiol 1994; 32: 2169-2174.
74. Plikaytis BB, Crawford JT, Woodley W et al. Rapid, amplification-based fingerprinting of Mycobacterium tuberculosis. J Gen Microbiol 1993; 139: 1537-1542.
75. Haas WH, Butler WR, Woodley CL, Crawford JT. Mixed-linker polymerase chain reaction: a new method for rapid fingerprinting of isolates of the Mycobacterium tuberculosis complex. J Clin Microbiol 1993; 31: 1293-1298.
76. Palittapongarnpim P, Chomyc S, Fanning A, Kunimoto D. DNA fingerprinting of Mycobacterium tuberculosis isolates by ligation-mediated polymerase chain reaction. Nucleic Acids Res 1993; 21: 761-762.
77. Goyal M, Young D, Zhang Y, Jenkins PA, Shaw RJ. PCR amplification of variable sequence upstream of katG gene to subdivide strains of Mycobacterium tuberculosis complex. J Clin Microbiol 1994; 32: 3070-3071.
78. Plikaytis BB, Marden JL, Crawford JT, Woodley CL, Butler WR, Shinnick TM. Multiplex PCR assay specific for multidrug-resistant strain W of Mycobacterium tuberculosis. J Clin Microbiol 1994; 32: 1542-1546.
79. Bloom BR, Murray CJL. Tuberculosis: commentary on a reemergent killer. Science 1992; 257: 1055-1064.
80. Centres for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons Florida and New York, 1988-1991. MMWR 1991; 40: 585-591.
81. Zhang Y, Heym B, Allen B et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
82. Banerjee A, Dubnau E, Quemard A et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-230.
83. Finken M, Kirschner P, Meier A et al. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993; 9: 1239-1246.
84. Tarkiff HE, Salazar L, Guerrero C et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
85. Heym B, Honore N, Truffot-Pernot C et al. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994; 344: 293-298.
86. Zhang Y, Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 1994; 34: 313-319.
87. Cole ST. Mycobacterium tuberculosis: drug resistance mechanisms. Trends Microbiol 1994; 2: 411-415.
88. Middlebrook G. Isoniazid resistance and catalase activity of tubercle bacilli. Am Rev Tuberc 1954; 69: 471-472.
89. Winder FG. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria, In: Ratledge C, Stanford J (eds) The biology of the mycobacteria, vol 1. London, Academic Press. 1982: 354-438.
90. Zhang Y, Garbe T, Young D. Transformation with katG restores isoniazid sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 1993; 8: 521-524.
91. Benveniste R, Davies J. Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem 1973; 42: 471-506.
92. Shoeb HA, Bowman BU, Ottolenghi AC et al. Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1985; 27: 404-407.
93. Johnsson K, Schultz PG. Mechanistic studies of the oxidation of isoniazid by the catalase-peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994; 116: 7425-7426.
94. Meissner G. The bacteriology of the tuberclc bacilli. In: Barry VC (ed) The chemotherapy of tuberculosis. London, Butterworths. 1964: 65-110.
95. Styblo K, Sutherland I. Epidemiology of tuberculosis in children. Bull Int Union Tuberc 1982; 57: 133-139.
96. Starke JR, Jacobs RF, Jereb J. Resurgence of tuberculosis in children. J Pediatr 1992; 120: 839-855.
97. Miller FJW, Seale RME, Taylor MD. Tuberculosis in children. London, JA Churchill, 1963.
98. Smith MHD. Tuberculosis in adolescents. Clin Pediatr 1967; 6: 9-15.
99. Nemir RL. Perspectives in adolescent tuberculosis: three decades of experience. Pediatrics 1986; 78: 399-405.
100. Centers for Disease Control. Tuberculosis morbidity - United States, 1992. MMWR 1993; 42: 696-704.
101. Centers for Disease Control. Expanded tuberculosis surveillance and tuberculosis morbidity United States, 1993. MMWR 1994; 43: 361-366.
102. Medical Research Council Cardiothoracic Epidemiology Group. Tuberculosis in children: a national survey of notifications in England and Wales in 1988. Arch Dis Child 1994; 70: 497-500.
103. Ormerod LP. Results of tuberculosis contact tracing: Blackburn 1982-90. Respir Med 1993; 87: 127-131.
104. Goodyear HM, Moore-Gillon JC, Price EH, Larcher VF, Savage MO, Wood CBS. Mycobacterial infection in an inner city children's hospital. Arch Dis Child 1993; 69: 229-231.
105. Delacourt C, Marie TM, Bonnerot V et al. Computed tomography with normal chest radiographs in tuberculous infection. Arch Dis Child 1993; 69: 430-432.
106. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72: 213-220.
107. Okot-Nwang M, Wabwire-Mangen F, Kagezi VBA. Increasing prevalence of tuberculosis among Mulago Hospital admissions, Kampala, Uganda (1985-89). Tubercle Lung Dis 1993; 74: 121-125.
108. Luo C, Chintu C, Bhat G et al. Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thiacetazone-free regimen. Tubercle Lung Dis 1994; 75: 110-115.
109. Dumois JA. Tuberculosis in children with HIV infection. Pediatr AIDS HIV Infect: fetus adolescent 1992; 3: 177-182.
110. Braun MM, Cauthen G. Relationship of the human immunodeficiency virus epidemic to pediatric tuberculosis and Bacillus Calmette-Guerin immunisation. Pediatr Infect Dis J 1992; 11: 220-227.
111. WHO. Tuberculosis/HIV research. WHO/TUB/92.167.
112. Barnes PF, Block AB, Davidson PT, Snider DE. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644-1650.
113. Moss WJ, Dedyo T, Suarez M, Nicholas SW, Abrams E. Tuberculosis in children infected with human immunodeficiency virus: a report of five cases. Pediatr Infect Dis J 1992; 11: 114-120.
114. Jones DS, Malecki JM, Bigler WJ, Witte JJ, Oxtoby MJ. Pediatric tuberculosis and human immunodeficiency virus infection in Palm Beach County, Florida. Am J Dis Child 1992; 146: 1166-1170.
115. Gutman LT, Moye J, Zimmer B, Tian C. Tuberculosis in human immunodeficiency virus exposed or infected United States children. Pediatr Infect Dis J 1994; 13: 963-968.
116. Muganga N, Nkuadiolandu A, Mashako LMN. Clinical manifestations of AIDS in children in Kinshasa. Pediatrie 1991; 46: 825-829.
117. Lepage P, Van de Perre P, Vliet GV et al. Clinical and endocrinologic manifestations in perinatally human immunodeficiency virus type 1-infected children aged 5 years or older. Am J Dis Child 1991; 145: 1248-1251.
118. Chintu C, Bhat G, Luo C et al. Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis. Pediatr Infect Din J 1993; 12: 499-504.
119. Sassan-Morokro M, De Cock HM, Ackah A et al. Tuberculosis and HIV infection in children in Abidjan, Cote d'Ivoire. Trans R Soc Trop Med Hyg 1994; 88: 178-181.
120. Chintu C, Luo C, Bhat G, Raviglione M, Du Pont H, Zumla A. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-1. Arch Dis Child 1993; 68: 665-668.
121. Hoyt L, Oleske J, Holland B, Connor E. Non tuberculous mycobacteria in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1992; 11: 354-360.
122. Rutstein RM, Cobb P, McGowan KL, Pinto-Martin J, Starr SE. Mycobacterium avium intracellulare complex infection in HIV-infected children. AIDS 1993; 7: 507-512.
123. Shata AMA. Diagnosis of tuberculosis in children. Dissertation of Masters in Tropical Paediatrics Degree, Liverpool School of Tropical Medicine 1994.
124. Joint Tuberculosis Committee. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1990; 45: 403-408.
125. Tuberculosis in Children. Guidelines for diagnosis, prevention and treatment (a statement of the Scientific Committees of the IUATLD). Bull Int Union Tuberc Lung Dis 1991; 66: 61-67.
126. Treatment of Tuberculosis. Guidelines for National Programmes. Geneva, World Health Organization, 1993,
127. American Academy of Pediatrics. Chemotherapy for tuberculosis in infants and children. Pediatrics 1992; 89: 161-165.
128. Centers for Disease Control. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994; 43: 66.
129. Humphries M. The management of tuberculous meningitis. Thorax 1992; 47: 577-581.
130. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for extrapulmonary tuberculosis: nine years experience. Ann Int Med 1986; 104: 7-12.
131. Alarcon F, Escalante L, Perez Y, Banda H, Chacon G, Duenas G. Tuberculous meningitis: short course of chemotherapy. Arch Neurol 1990; 47: 1313-1317.
132. Jacobs RF, Sunakorn P, Chotpitayasunonah T, Pope S, Kelleher K. Intensive short course chemotherapy for tuberculosis meningitis. Pediatr Infect Dis J 1992; 11: 194-197.
133. Palur R, Rajshekhar V, Chandy MJ, Joseph T, Abraham J. Shunt surgery for hydrocephalus in tuberculous meningitis: a long-term follow-up study. J Neurosurg 1991; 74: 64-69.
134. Seth V, Beotra A, Bagga A, Seth S. Drug therapy in malnutrition. Ind J Pediatr 1992; 92: 1341-1346.
135. Sudra P, Tan Dam G, Kochi A. Tuberculosis; a global overview of the situation. Bull World Health Organ 1992; 70: 149-159.
136. Ormerod LP. Respiratory tuberculosis. In: Davies PDO (ed) Clinical tuberculosis London, Chapman and Hall. 1994: 73-92.
137. Humphries MJ, Lam WK, Teah R. Non-respiratory tuberculosis. In: Davies PDO (ed) Clinical tuberculosis. London, Chapman and Hall. 1994: 93-104.
138. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6 month, 3 times weekly regimens for smear positive pulmonary tuberculosis, including assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143: 700-706.
139. Villorina ME, Geiter LJ, Simone PM. The multidrug resistant tuberculosis challenge to public health efforts to control tuberculosis: 1992. Public Health Rep 1992; 107: 616-625.
140. Nolte FS, Metchock M, McGowan JE et al. Direct detection of M. tuberculosis in sputum by polymerase chain reaction and DNA hybridization. J Clin Microbiol 1993; 31: 1777-1782.
141. Godfrey-Faussett P. DNA finger printing, a powerful tool for the study of tuberculosis. In: Davies PDO (ed) Clinical tuberculosis. London, Chapman and Hall, 1994: 391-400.
142. Rieder HL. Misbehaviour of a dying epidemic: a call for less speculation and better surveillance. Tubercle Lung Dis 1992; 73: 181-183.
143. Mass DW, Des Prez RM. Tuberculosis and AIDS: a historical perspective on recent developments. Am J Med 1994; 96: 439-450.
144. De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. J Am Med Assoc 1992; 268: 1581-1587.
145. Joint Tuberculosis Committee of the British Thoracic Society. Guidelines on the management of tuberculosis and HIV infection in the United Kingdom. BMJ 1992; 304: 1231-1233.
146. Selwyn PA, Hartel D, Lewis VA et al. A prospective study of the risk of tuberculosis among intravenous drug users with HIV infection. N Engl J Med 1989; 320: 545-550.
147. Hamburg MA, Frieden TR. Tuberculosis transmission in the 1990s. N Engl J Med 1994; 330: 1750-1751.
148. Alland D, Kalkut GE, Moss AR et al. Transmission of tuberculosis in New York city - an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
149. Small PM, Hopewell PC, Singh SP et al. The epidemiology of tuberculosis in San Francisco - a population based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
150. Gilks CF. Prophylaxis for HIV-associated infections in the developing world. J Antimicrob Chemother 1993; 31 Suppl B: 119-128.
151. Shafer RW, Chirgwin KD, Glatt AE et al. HIV prevalence, immunosuppression and drug resistance in patients with tuberculosis in an area endemic for AIDS. AIDS 1991; 5: 399-405.
152. Gilks CF, Brindle RJ, Mwachari C et al. Disseminated M. avium infection among HIV-infected patients in Kenya. J AIDS (in press).
153. Batungwanayo J, Taelman H, Allen S et al. Pleural effusion, tuberculosis and HIV-1 infection in Kigali, Rwanda. AIDS 1993; 7: 73-79.
154. Lucas SB, De Cock KM, Hounnou A et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994; 308: 1531-1533.
155. Brindle RJ, Nunn PP, Batchelor BIF et al. Infection and morbidity in patients with tuberculosis in Nairobi, Kenya. AIDS 1993; 7: 1469-1474.
156. Nunn P, Kibuga D, Gathua S et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 377: 627-630.
157. Okwera A, Whalen C, Byekwaso F et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-1328.
158. World Health Organization. The HIV/AIDS and tuberculosis epidemics - implications for TB control. WHO Geneva 1994 document WHO/TB/CARG(4)/94.4.
159. Editorial. The global challenge of tuberculosis. Lancet 1994; 344: 277-278.
160. Hinshaw HC, Feldman WH. Streptomycin in treatment of clinical tuberculosis: a preliminary report. Proc Staff Meetings Mayo Clin 1945; 20: 313-318.
161. Robitzek EH, Selikoff IJ. Hydrazine derivatives of isonicotinic acid (Rimifan, Marsilid) in the treatment of active progressive caseous - pneumonic tuberculosis: a preliminary report. Am Rev Tuberc 1952; 65: 402-428.
162. Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. BMJ 1950; 2: 1073-1085.
163. East African/British Medical Research Councils. Controlled clinical trial of short course (6 months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-1085.
164. East African/British Medical Research Councils. Controlled clinical trial of short course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis (second report). Lancet 1973; 1: 1331-1339.
165. East African/British Medical Research Councils. Controlled clinical trial of short course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis (third report). Lancet 1974; 2: 237-240.
166. Mackaness GB. The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc Pulmon Dis 1956; 74: 718-728.
167. Dickinson JM, Aber VR, Mitchison DA. Bactericidal activity of streptomycin, isoniazid, rifampicin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 1977; 116: 627-635.
168. Snider DE, Graczyk J, Bek E, Rogowski J. Supervised six months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampicin and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130: 1091-1094.
169. Combs DL, O'Brian RJ, Geiter LJ. USHPS tuberculosis short course chemotherapy trial 21: effectiveness, toxicity and acceptability. The report of final results. Ann Intern Med 1990; 112: 397-406.
170. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double blind placebo controlled clinical trial of three anti-tuberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
171. Inderlied CB. Antimycobacterial agents: in vitro susceptibility testing, spectrums of activity, mechanisms of action and resistance and assays for activity in biological fluids. In: Lorian V (ed) Antibiotics in laboratory medicine. New York, Williams and Wilkins. 1991: 134-197.
172. Takayama K, Qureshii N. Structure and synthesis of lipids. In: Kubica GP, Wayne LG (eds) The mycobacteriæ a source book (part A). New York, Marcel Dekker. 1984.
173. Kruger-Thierner E. Isonicotinic acid hypothesis of the antituberculous action of isoniazid. Am Rev Tuberc Pulmon Dis 1958; 77: 364-367.
174. Krishamurti CR. Isonicotinic hydrazide. In: Corcoran JW, Hahn FF (eds) Antibiotics: mechanism of action of antimicrobial and anti-tumour agents. New York. Springer, Verlag, 1975: 623-652.
175. Poso H, Paulin L, Brander E. Specific inhibition of spermidine synthase from mycobacteria by ethambutol. Lancet 1983; 1: 1418.
176. Takayama K, Kilburn N. Inhibitors of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989; 33: 1493-1499.
177. Heifets LB, Iseman MD, Crowle AJ, Lindholm-Levy PJ. Pyrazinamide is not active in vitro against Mycobacterium avium complex. Am Rev Respir Dis 1986; 134: 1287-1288.
178. Brickner SJ, Manninen PR, Vlanowicz DA et al. Synthesis and antibacterial activity of novel, multicyclic fused-ring oxazolidinones. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy, 1993, New Orleans, Abstract No. 72.
179. Kilburn J, Glickman S, Brickner S et al. In vitro antimycobacterial activity of novel multicyclic, fused-ring oxazolidinones. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy, 1993, New Orleans, Abstract No. 73.
180. Gangadharam PRJ. Gangamicin, a potential antimycobacterial drug. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy, 1993, New Orleans, Abstract No. 77.
181. Cremieux A, Chevalier J, Sharples D et al. Antimicrobial activity of 9-acridinones and 9-thro-alkylacridines. New insight into the mechanism of action of these drugs. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy, 1993, New Orleans, Abstract No. 78.
182. Deitz WH, Cook TM, Goss WA. Mechanism of actions of nalidixic acid on Escherichia coli III conditions required for lethality. J Bacteriol 1966; 91: 768-773.
183. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Clin Infect Dis 1992; 15 Suppl 1: 282-295.
184. Inderlied CB, Bermudez LE, Barbara-Burnham L, Wu M, Young L. In vitro and macrophage activity of KRM 1648 against the Mycobacterium avium complex (MAC). 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy, 1993, New Orleans, Abstract No, 69.
185. Hosoe K, Konishi A, Mae T, Fujii K, Hadaka T, Ohashi T. Pharmacokinetics of KRM-1648, a new rifampicin derivative, in rats and dogs. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy, 1993, New Orleans, Abstract No. 70.
186. Pharma Projects. May 1994, J4A, a 954-955.
187. Brogden RN, Filton A. Rifampicin - a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47; 983-1009.
188. Dickinson JM, Mitchison DA. In vitro properties of rifampicin (MDL 47B) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 113-118.
189. Dhople AM. In vitro activity of 2′2′ bipyridyl analogues against Mycobacterium avium and Mycobacterium tuberculosis. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy, 1993, New Orleans, Abstract No. 74.
190. Pharma projects. May 1994, J4A, a 953.
191. Pharma projects. May 1994, J4A, a 952.
192. Gay JD, deYoung DR, Roberts GD. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, Mycobacterium avium complex, M. chelonei, M. fortuitum and M. kansasii. Antimicrob Agents Chemother 1984; 26: 94-96.
193. Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesised quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1259-1263.
194. Robbins MJ, Felmingham D, Gruneberg RN. Comparative in-vitro activity of CI-960 (PD127,391), a new fluoroquinolone, against Mycobacterium tuberculosis, and Mycobacterium 'avium-intracellulare' complex. 5th European Congress of Clinical Microbiology and Infectious Diseases, 1991, Oslo, Abstract No. 1720.
195. Saito H, Tomioka H, Sato K. In vitro antimycobacterial activity of OPC-17116 a newly synthesised quinolone. 31st Interscience Congress on Antimicrobial Agents and Chemotherapy, 1991, Chicago, Abstract no. 1468.
196. Felmingham D, Robbens MJ, Ghosh G et al. In vitro studies with Du 6859a, a new fluroquinolone antimicrobial. 31st Interscience Congress on Antimicrobial Agents and Chemotherapy, 1991, Chicago, Abstract no. 981.
197. Wise R. Comparative penetrations of selected fluoroquinolones into respiratory tract fluids and tissues. Am J Med 1991; 91: 67s-70s.
198. Cartier MB, Scorreaux B, Zereborgh P. Cellular uptake, localisation and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26 Suppl B: 27-39.
199. Piersimoni C, Morbiducci V, Bornigia S et al. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis. Am Rev Respir Dis 1992; 146: 1445-1447.
200. Bergan T, Dalhoff A, Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection 1988; 16 Suppl 1: s3-s13.
201. Chadwick M, Nicholson G, Gaya H. Brief report: combination chemotherapy with ciprofloxacin for infection with M. tuberculosis in mouse model. Am J Med 1989; 87 Suppl 5a: 35s-36s.
202. Anagnostopula U, Rapti A, Vagratzakis E, Marinis E, Kapetaneas S. Ciprofloxacin in pulmonary tuberculosis treatment. Am Rev Respir Dis 1990; 141: a436.
203. Kahana L, Spino M. Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. DICP: Ann Pharmacother 1991; 25: 919-924.
204. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short term chemotherapy for pulmonary tuberculosis. Chest 1993; 104: 1194-1198.
205. Kennedy N, Fox R, Kisyombe GM et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-1551.
206. Berlin OGW, Young LS, Bruckner DA. In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother 1987; 19: 611-615.
207. Lode H, Hoffke G, Olschewski P et al. Pharmacokinetics of ofloxacin after parental and oral administration. Antimicrob Agents Chemother 1987; 31: 1338-1342.
208. Heifets LB, Lindholm-Levy PJ. Bacteristatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 1987; 68: 267-276.
209. Truffot-Pernot C, Ji B, Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria in vitro and mouse experiments. Tubercle 1991; 72: 57-64.
210. Tsukamura M, Nakamura E, Yoshi S, Amano H. Therapeutic effect of a new antibacterial substance, ofloxacin (DL 8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 352-356.
211. Davidson DT, Le HQ. Drug treatment of tuberculosis 1992. Drugs 1992; 43: 651-673.
212. Cambau E, Sougakoff W, Besson M, Truffot-Pernot M, Grosset J, Jarlier V. Selection of gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 479-483.
213. Japanese Ministry of Health and Welfare. "Sparfloxacin and photosensitivity"; Report No. 127, 1994.
214. Parish HJ. A history of immunization. Edinburgh, E and S Livingstone, 1965: 92-106.
215. Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tubercle Lung Dis 1992; 73: 252-261.
216. Hart PD, Sunderland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 1977; 2: 292-295.
217. Zhang Y, Wallace RJ, Mazurek GH. Genetic differences between BCG substrains. Tubercle Lung Dis 1995; 76: 43-50.
218. Lagranderie M, Ravisse P, Marchal G et al. BCG-induced protection in guinea-pigs vaccinated and challenged via the respiratory route. Tubercle Lung Dis 1993; 74: 38-46.
219. Lotte A, ten Dam HG, Henderson R. Second IUATLK study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc 1988; 63: 47-83.
220. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR (ed) Tuberculosis: pathogenesis protection and control. Washington, DC, American Society for Microbiology. 1994: 531-557.
221. Praveen KN, Smikle MF, Prabhakar P et al. Outbreak of Bacillus Calmette-Guérin-associated lymphadenitis and abscesses in Jamaican children. Pediatr Infect Dis J 1990; 9: 890-893.
222. Romanus V, Svensson A, Hallander HO. The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989. Tubercle Lung Dis 1992; 73: 150-161.
223. Gonzalez B, Moreno S, Burdach R et al. Clinical presentation of Bacillus Calmette-Guérin infections in patient with immunodeficiency. Pediatr Infect Dis J 1989; 8: 201-206.
224. Braun MM, Cauthen G. Relationship of the human immunodeficiency virus epidemic to pediatric tuberculosis and Bacillus Calmette-Guérin immunization. Pediatr Infect Dis J 1992; 11: 220-227.
225. Weltman AC, Rose DN. The safety of Bacille Calmette-Guérin vaccination in HIV infection and AIDS. AIDS 1993; 7: 149-157.
226. Lallemont-Le Coeur S, Lallemont M, Chenier D et al. BCG immunization in infants born to HIV-1 seropositive mothers. AIDS 1991; 5: 195-199.
227. Centers for Disease Control. BCG vaccination and pediatric HIV infection - Rwanda 1988-90. MMWR 1991; 40: 833-835.
228. WHO. Expanded progam on immunization: joint WHO/UNICEF statement on immunization and AIDS. Wkly Epidemiol Rec 1987; 62: 53-54.
229. Cox RA, Downs M, Niemans RE et al. Immunogenetic analyses of human tuberculosis. J Infect Dis 1988; 158: 1302-1308.
230. Smith PG, BCG vaccination. In: Davies PDO (ed) Clinical tuberculosis. London, Chapman and Hall. 1994: 297-310.
231. Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention: first report. Bull World Health Organ 1979; 57: 819-827.
232. Colditz GA, Brewer TK, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271: 698-702.
233. Brewer TF, Colditz GA. Relationship between Bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 1995; 20: 126-135.
234. Styblo K. Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Rev Infect Dis 1989; 11 Suppl 2: S339-S346.
235. IUATLD. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guérin (BCG) in countries with a low prevalence of tuberculosis. Tubercle Lung Dis 1994; 75: 179-181.
236. Romanus V. Tuberculosis in Bacillus Calmette-Guérin-immunized and unimmunized children in Sweden: a ten year evaluation following the cessation of general Bacillus Calmette-Guérin immunization of the newborn in 1975. Pediatr Infect Dis J 1987; 6: 272-280.
237. Trnka L, Danková D, Sandova E. Six years' experience with the discontinuation of BCG vaccination 1. Risk of tuberculosis infection and disease. Tubercle Lung Dis 1993; 74: 167-172.
238. Trnka L, Dankova D, Sandova E. Six years' experience with the discontinuation of BCG vaccination 2. Cost and benefit of mass BCG vaccination. Tubercle Lung Dis 1993; 74: 288-292.
239. Trnka L, Danikova D, Sandova E. Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium/intracellular complex. Tubercle Lung Dis 1994; 75: 348-352.
240. Booy R, Hodgson S, Carpenter I. et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344: 362-366.
241. Springett VH, Sutherland I. A re-examination of the variations of efficacy of BCG vaccination against tuberculosis in clinical trials. Tubercle Lung Dis 1994; 75: 227-233.
242. Editorial. New tuberculins. Lancet 1984; 1: 199-200.
243. Editorial. Bettering BCG. Lancet 1992; 339: 40-41.
244. Koch R. An address on bacteriological research delivered before the International Medical Congress, held in Berlin, August 1890. BMJ 1890; 2: 380-383.
245. Fowler WC. A preliminary report on the treatment of tuberculosis with turtle vaccine. Tubercle 1930; 12: 7-12.
246. MacAssey L, Saleeby GW (eds). Spahlinger contra tuberculosis 1908-1931. New York, John Bale, Sons and Danielsson Ltd, 1934.
247. Spahlinger H. Note on the treatment of tuberculosis. Lancet 1922; 1: 5-8.
248. Grange JM. The mystery of the mycobacterial persister. Tubercle Lung Dis 1992; 73: 249-251.
249. Stanford JL, Stanford CA, Rook GAW, Grange JM. Immunotherapy for tuberculosis ..... investigative and practical aspects. Clin Immunother 1994; 1: 430-440.
250. Stanford JL, Rook GA, Bahr GM et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990; 8: 525-530.
251. Brown JAK, Stone MM, Sutherland I. BCG vaccination of children against leprosy in Uganda. BMJ 1966; 1: 7-14.
252. Kardjito T, Beck JS, Grange JM, Stanford JL. A comparison of the responsiveness to four new tuberculins among Indonesian patients with pulmonary tuberculosis and healthy subjects. Eur J Respir Dis 1986; 69: 142-145.
253. Stanford JL, Stanford CA, Ghazi-Saidi K et al. Vaccination and skin test studies on the children of leprosy patients. Int J Leprosy 1989; 57: 38-44.
254. Ganapati R, Revankar CR, Lockwood DN et al. A pilot study of three potential vaccines for leprosy in Bombay. Int J Leprosy 1989; 57: 33-37.
255. Nye PM, Price JL, Revankar CR, Rook GAW, Stanford JL. The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin testing with mycobacterial reagent mixtures. Lepr Rev 1983; 54: 9-18.
256. Nye PM, Stanford JL, Rook GAW et al. Suppressor determinants of mycobacteria and their potential relevance to leprosy. Lepr Rev 1986; 57: 147-157.
257. Pozniak A, Stanford JL, Rook GAW, Johnson N McI. A tentative introduction of immunotherapy into the treatment of tuberculosis. Bull Int Union Tuberc 1987; 62: 39-40.
258. Bahr GM, Shaaban MA, Gabriel M et al. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 1990; 71: 259-266.
259. Vicirca A, Dominino J, Valentini E, Hartopp R, Bottasso OA. A pilot study of immunotherapy with M. vaccae against tuberculosis. Tubercle Lung Dis 1994; 75 Suppl 3: 47-48.
260. Onyebujoh P, Abdulmumini T, Robinson S, Rook GAW, Stanford JL. Immunotherapy for tuberculosis in African conditions. Respir Med 1995; 89: 199-207.
261. Farid R, Etemadi A, Mehvar M, Stanford JL, Dowlati Y, Velayati AA. Mycobacterium vaccae immunotherapy in the treatment of multi-drug-resistant tuberculosis: a preliminary report. Iranian J Med Sci 1994; 19: 37-39.
262. Stanford JL, Onyebujoh PC, Rook GA, Grange JM, Pozniak A. Old plague, new plague, and a treatment for both? AIDS 1993; 7: 1275-1277.
263. Bahr GM, Sattar MA, Stanford JL et al. HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Ann Rheum Dis 1989; 48: 63-68.
264. Khoo SH, Wilkins EGL, Fraser I, Stanford JL. Lack of T-cell response to common mycobacterial antigens in HIV-infected individuals consequence or a co-factor? IX International Conference on AIDS, Berlin, 6-11 June 1993. Abstract No. PO-A24-0551.
265. Bottasso OA, Ingledew N, Keni M et al. Cellular immune response to common mycobacterial antigens in subjects seropositive for Trypanosoma cruzi. Lancet 1994; 344: 1540-1541.
266. Stanford JL. The history and future of vaccination and immunotherapy for leprosy. Trop Geogr Med 1994; 46: 93-107.
267. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72: 1-6.
268. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc 1990; 65: 6-24.
269. International Union Against Tuberculosis and Lung Disease. Tuberculosis guide for high prevalence countries, 2nd edn. Paris, IUATLD, 1993.
270. World Health Organization. Managing tuberculosis at the district level. Geneva, WHO, 1993.
271. De Cock KM, Screening for tuberculosis and HIV in resource-poor countries. Lancet 1995; 345: 873-874.
272. Madico G, Gilman RH, Checkley W et al. Community infection ratio as an indicator for tuberculosis control. Lancet 1995; 345: 416-419.
273. FitzGerald JM. The downside of isoniazid chemoprophylaxis, Lancet 1995; 345: 404.
274. Tayler EM. Montoux screening for tuberculosis. Lancet 1995; 345: 930-931.
275. Gebre N, Karlsson U, Jonsson G et al. Improved microscopical diagnosis of pulmonary tuberculosis in developing countries. Trans R Soc Trop Med Hyg 1995; 89: 191-193.
276. Parry CM, Kamoto O, Harries AD et al. The use of sputum induction for establishing a diagnosis in patients with suspected pulmonary tuberculosis in Malawi. Tubercle Lung Dis 1995; 76: 72-76.
277. Murray CJ, De Jonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305-1308.
278. Sepkowitz KA, Raffalli J, Riley L, Kiehn TE, Armstrong D. Tuberculosis in the AIDS era. Clin Microbial Rev 1995; 8: 180-199.
279. Sepkowitz KA. AIDS, tuberculosis and the health care worker. Clin Infect Dis 1995; 20: 232-242.
280. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet 1994; 343: 647-648.
281. Gangadharan PRJ. Chemotherapy of tuberculosis under programme conditions with special relevance to India. Tubercle Lung Dis 1994; 75: 241-244.
282. Chakraborty AK. Drugs are not enough. Tubercle Lung Dis 1994; 75: 316-317.
283. Uplekar MW, Shepard DS. Treatment of tuberculosis by private general practitioners in India. Tubercle 1991; 72: 284-290.
284. Akhtar T, Imran M. Management of tuberculosis by practitioners of Peshawar. J Pak Med Assoc 1994; 44: 280-282.
285. Solomon S, Anuradha S, Rajasekaran S. Trend of HIV infection in patients with pulmonary tuberculosis in South India. Tubercle Lung Dis 1995; 76: 17-19.
286. Onozaki I, Shakya TM. Feasibility study of a district tuberculosis control programme with an 8-month short-course chemotherapy regimen utilizing the integrated health service network under field conditions in Nepal. Tubercle Lung Dis 1995; 76: 65-71.